Recombinant Human CTSK

• Cat.No.: CTSK-690H
• Product Overview: Recombinant Human CTSK was expressed in insect cells.

Specification

• Cat. No.: CTSK-690H
• Description: The protein encoded by this gene is a lysosomal cysteine proteinase involved in bone remodeling and resorption. This protein, which is a member of the peptidase C1 protein family, is predominantly expressed in osteoclasts. However, the encoded protein is also expressed in a significant fraction of human breast cancers, where it could contribute to tumor invasiveness. Mutations in this gene are the cause of pycnodysostosis, an autosomal recessive disease characterized by osteosclerosis and short stature. This gene may be subject to RNA editing.
• Source: Insect cells
• Molecular Mass: ~26kDa
• Purity: ≥95% as determined by SDS­PAGE.
• Concentration: 0.023mg/ml
• Formulation: Liquid. In 50mM sodium acetate, pH 5.5, containing 50mM sodium chloride, 0.5mM EDTA and 5mM DTT.
• Specific Activity: ≥1''500mU/mg protein.One unit is defined as the amount of enzyme that will hydrolyze 1µmol Z-Phe-Arg-AMC substrate per min. at 37oC in 50mM sodium acetate, pH 5.5, containing 2.5mM EDTA, 0.01% Trition X-100 and 1mM DTT.
• Storage: Stable for at least 6 months after receipt when stored at -80°C.
• OfficialSymbol: CTSK
• Tag: Non

Gene Information

• Gene Name: CTSK cathepsin K [ Homo sapiens ]
• Synonyms: CTSK; cathepsin K; CTSO; PKND; PYCD; CTS02; CTSO1; CTSO2; MGC23107; cathepsin K; cathepsin O; cathepsin X; cathepsin O1; cathepsin O2; OTTHUMP00000032938
• Gene ID: 1513
• mRNA Refseq: NM_000396
• Protein Refseq: NP_000387
• MIM: 601105
• UniProt ID: P43235
• Chromosome Location: 1q21
• Pathway: Lysosome; Osteoclast Signaling; Osteoclast differentiation; Rheumatoid arthritis; Toll-like receptor signaling pathway
• Function: cysteine-type endopeptidase activity; cysteine-type peptidase activity; peptidase activity

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.